Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

SWHFX vs. QAAGZX: which is better?

Bottom line

SWHFX vs QAAGZX: the short answer

SWHFX (Schwab Health Care Fund) and QAAGZX (T. Rowe Price Health Sciences Portfolio) share a meaningful slice of their top holdings — about 73% by weight.

But QAAGZX is far broader, holding 277 positions to 80 for SWHFX, so beyond the top names it adds exposure SWHFX doesn't have.

SWHFX is cheaper at 0.8% vs 0.86% — a difference of $6.00 a year per $10,000 invested.

Over five years, SWHFX returned +6.5% a year vs +4.1% for QAAGZX.

Updated Nov 19, 2026

SWHFX vs QAAGZX side by side

SWHFXQAAGZX
TypeMutual fundETF
Fund familySchwabT. Rowe Price
CategoryHealth Care SectorHealth Care Sector
Expense ratio0.8%0.86%
Annual cost per $10k$80$86
10-yr cost on $10k (prospectus)$990$1,061
Max front load—None
12b-1 fee0%0%
1-yr return+15.9%+18.1%
5-yr return (annualized)+6.5%+4.1%
10-yr return (annualized)+8.1%+9.0%
Best quarter+15.3%+23.4%
Worst quarter−12.1%−15.8%
Net assets (fund)$642.3M$751.7M
Number of holdings80277
Portfolio turnover41%65%
Returns as ofDec 31, 2025Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearSWHFXQAAGZXDifference
2025+15.9%+18.1%−2.2%
2024+0.1%+1.7%−1.6%
2023+0.7%+3.0%−2.3%
2022−4.7%−12.5%+7.8%
2021+23.3%+13.1%+10.2%
2020+12.9%+29.6%−16.8%
2019+17.6%+29.0%−11.3%
2018+4.0%+1.1%+2.9%
2017+20.2%+27.6%−7.4%
2016−4.4%−10.5%+6.1%

Source: Fund prospectus bar charts

Holdings overlap

14 of SWHFX's top 25 holdings also appear in QAAGZX's top 25.

Shared top holdings
HoldingSWHFXQAAGZX
Eli Lilly & Co13.92%14.06%
Johnson & Johnson6.94%6.64%
AbbVie Inc5.81%5.12%
Merck & Co Inc4.98%4.00%
UnitedHealth Group Inc4.74%5.88%
Gilead Sciences Inc3.24%2.79%
Amgen Inc2.58%1.80%
Bristol-Myers Squibb Co2.44%2.12%
Thermo Fisher Scientific Inc2.16%2.53%
Stryker Corp2.11%1.78%
Vertex Pharmaceuticals Inc1.89%2.26%
Abbott Laboratories1.60%1.91%
Danaher Corp1.47%1.44%
Elevance Health Inc1.45%1.54%

Source: SEC Form N-PORT

SWHFX top 10

  1. Eli Lilly & Co — 13.92%
  2. Johnson & Johnson — 6.94%
  3. AbbVie Inc — 5.81%
  4. Merck & Co Inc — 4.98%
  5. UnitedHealth Group Inc — 4.74%
  6. Gilead Sciences Inc — 3.24%
  7. Novartis AG — 2.92%
  8. Amgen Inc — 2.58%
  9. Bristol-Myers Squibb Co — 2.44%
  10. Medtronic PLC — 2.29%

QAAGZX top 10

  1. Eli Lilly & Co — 14.06%
  2. Johnson & Johnson — 6.64%
  3. Unitedhealth Group Inc — 5.88%
  4. Abbvie Inc — 5.12%
  5. Merck & Co. Inc. — 4.00%
  6. Gilead Sciences Inc — 2.79%
  7. Thermo Fisher Scientific Inc — 2.53%
  8. Vertex Pharmaceuticals Inc — 2.26%
  9. Bristol-myers Squibb Co — 2.12%
  10. Abbott Laboratories — 1.91%

FAQ

What is the difference between SWHFX and QAAGZX?
SWHFX (Schwab Health Care Fund) and QAAGZX (T. Rowe Price Health Sciences Portfolio) share a meaningful slice of their top holdings — about 73% by weight. But QAAGZX is far broader, holding 277 positions to 80 for SWHFX, so beyond the top names it adds exposure SWHFX doesn't have.
Which is cheaper, SWHFX or QAAGZX?
SWHFX has the lower expense ratio (0.8%).
Should I own both SWHFX and QAAGZX?
Owning both adds little diversification because their portfolios overlap heavily; most investors pick one.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.